Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.45 |
| ▸ | PDE4A | P27815 | 5/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945901 | 0.89 | ATM (0.53) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL1943501 | 0.87 | MAPT (0.47) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL2328928 | 0.84 | MAPT (0.47) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL5054515 | 0.81 | SMN1; SMN2 (0.60) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL30799166 | 0.81 | MAPT (0.47) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL1947274 | 0.81 | MAPT (0.35) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL1947210 | 0.80 | ALDH1A1 (0.44) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL1546666 | 0.79 | MAPT (0.45) | MAPTSMN1; SMN2GLAADORA2BADORA2A | |
| SCHEMBL1946405 | 0.78 | ALDH1A1 (0.50) | MAPTSMN1; SMN2ADORA2BADORA2APDE4A | |
| SCHEMBL2685597 | 0.78 | MAPT (0.44) | MAPTSMN1; SMN2GLAADORA2BADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2022-12-22 | — | — | US | disclosed |
| EP-3735413-B1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD (IN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2021-03-11 | — | — | US | disclosed |
| WO-2019135259-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | IMPETIS BIOSCIENCES LTD. (IN) | 2019-07-11 | — | — | WO | disclosed |
| EP-2616470-B1 | PURINE COMPOUNDS AS PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LTD (IN) | 2016-10-12 | — | — | EP | disclosed |
| EP-2616470-B1 | PURINE COMPOUNDS AS PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS, THEIR PROCESS AND MEDICINAL APPLICATIONS | ADVINUS THERAPEUTICS LTD (IN) | 2016-10-12 | — | — | EP | disclosed |
| EP-2499142-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2016-09-21 | — | — | EP | disclosed |
| EP-2499142-B1 | SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS, ITS PREPARATION AND USES THEREOF | ADVINUS THERAPEUTICS LTD (IN) | 2016-09-21 | — | — | EP | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| US-9284316-B2 | Substituted fused pyrimidine compounds | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2016-03-15 | — | — | US | disclosed |
| WO-2003042214-A2 | A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2003-05-22 | — | — | WO | disclosed |
| EP-0559893-B1 | XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO KK (JP) | 1999-02-03 | — | — | EP | disclosed |
| EP-0686155-B1 | XANTHINE DERIVATIVES AS ADENOSINE A1 RECEPTOR ANTAGONISTS | MERRELL PHARMA INC (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5756735-A | ADENOSINE A2 RECEPTOR ANTAGONISTS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0449175-B1 | Selective adenosine receptor agents | MERRELL PHARMA INC (US) | 1997-07-30 | — | — | EP | disclosed |
| EP-0386675-B1 | Xanthine derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-06-05 | — | — | EP | disclosed |
| EP-0559893-A1 | XANTHINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5068236-A | Diuretics, renal protective agents and hypotensives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1991-11-26 | — | — | US | disclosed |
| EP-0449175-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1991-10-02 | — | — | EP | disclosed |
| EP-0386675-A2 | Xanthine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402927-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA1, ADORA2B | MAPT 918/4885SMN1; SMN2 2893/4885GLA 1089/4885 |
| US-20210070764-A1 | TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADORA2A, ADORA3, ADORA1 | MAPT 662/4885SMN1; SMN2 2901/4885GLA 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.